Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children. We have generated an epitope-specific RSV vaccine by grafting a neutralizing epitope (F-epitope) in its native conformation into an immunoglobulin scaffold. The resulting antibody fusion exhibited strong binding affinity to Motavizumab, an RSV neutralizing antibody, and effectively induced potent neutralizing antibodies in mice. This work illustrates the potential of the immunoglobulin molecule as a scaffold to present conformationally constrained B-cell epitopes.
| Original language | English |
|---|---|
| Pages (from-to) | 14531-14534 |
| Number of pages | 4 |
| Journal | Angewandte Chemie - International Edition |
| Volume | 54 |
| Issue number | 48 |
| DOIs | |
| State | Published - Nov 23 2015 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- RSV vaccine
- antibodies
- conformations
- polypeptides
- protein engineering
Fingerprint
Dive into the research topics of 'An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver